Strategic Therapeutics Inotrem focuses on a personalized medicine approach targeting the TREM-1 inflammatory pathway, with nangibotide as a lead candidate for life-threatening conditions such as septic shock and severe COVID-19, presenting a clear high-need market and potential for hospital-based sales and companion diagnostics partnerships.

Companion Diagnostics A strategic collaboration with Roche Diagnostics to develop the sTREM-1 assay enables targeted patient selection, offering a compelling value proposition for both payer-driven outcomes and life-cycle management through diagnostic-adjacent sales.

Clinical Progress Lead drug nangibotide has Phase II signals and a PRIME designation from EMA plus FDA Fast Track, indicating accelerated regulatory potential and a faster route to market in septic shock, which can short sales cycles with hospital systems and research networks.

Leadership & Growth Recent governance and leadership additions, including a new Chairman and CTO with manufacturing expertise, bolster investor confidence and readiness for scale-up manufacturing and global collaborations, creating avenues for partner- to-sell opportunities in bio/pharma landscapes.

Strategic Expansion Diversification into antibody-based programs and a monoclonal antibody initiative expand the potential addressable market beyond acute care sepsis to chronic inflammatory diseases, offering cross-sell opportunities with existing clinical and research partnerships.